Escolar Documentos
Profissional Documentos
Cultura Documentos
By Steve Painter
The AIDS pandemic is a disaster for humanity, but a gold mine for
some multinational chemical companies, it seems. While AIDS is still
spreading in advanced countries such as Australia and the USA, nine
out of 10 new HIV infections are now occurring in the Third World.
However, most treatments coming out of the laboratories of North
America and Europe are affordable only in the richest countries.
In the US, a year's supply of AZT for one person costs around
US$8000, perhaps okay for those who have adequate medical insurance,
but a disaster for those who don't. US AIDS activists say these prices
don't reflect the drug's production cost; bootleg supplies are much
cheaper, though illegal. Australian prices for patented AZT are even
higher, largely because the drug companies are aware that Medicare
will pick up the tab.
In 1989, NCI director Sam Broder and several colleagues wrote to the
New York Times saying, "one of the key obstacles to the development of
AZT was that Burroughs-Wellcome did not work with live AIDS virus nor
wish to receive samples from AIDS patients".
It seems the prices of other AIDS drugs are also kept outrageously
high by the fact that their patents are owned by private chemical
companies. Acyclovir, another Wellcome line, netted the company around
$400 million last year. This one is more established than AZT, having
been on the shelves for nearly a decade.
Another company, Roche, controls ddI and ddC, which are similar to
AZT and often used in conjunction with it. They cost about two-thirds
the price of AZT. Roche also sells Bactrim, used to fight pneumonia
and urinary infections in people with AIDS. Private multinational
companies control most of the research into AIDS because they have
budgets many times larger than those of most government research
bodies.
--- Tm_Write Version 1.30 --- Get ALL the News That Doesn't Fit -
Subscribe Today!